[Exclusivity of data in drug registration files and Israel's international status with regard to intellectual property rights protection].
Protecting intellectual property rights encourages creativity and innovation, which are key measures for research and development of new drugs and also promotes the introduction of drugs to new markets. Over the past years, many countries have enacted laws implementing the protection of data in drug registration files. Until recently, Israel has not provided any form of data protection. Current moves focus on new legislation granting exclusivity in the marketing of innovative drugs. Although controversial, this legislation aims to secure balance in Israel between the innovative pharmaceutical companies and the public's interest in competitive generic drugs.
Lipschitz
Yoel
Y
The Israeli Center for Technology Assessment in Health Care, The Gertner Institute for Epidemiology and Health Policy Research, Tel Hashomer. YOEL.LIPSCHITZ@MOH.HEALTH.GOV.IL
Tamir
Orly
O
Shemer
Joshua
J
D003309:Copyright / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D004358:Drug Therapy / Q000706:statistics & numerical data*; D018973:Intellectual Property; D007557:Israel; D012042:Registries